pp-113 Cream
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
Indication: Axillary osmidrosis (underarm odor condition) in patients requiring localized dermatologic therapy
Clinical stage: Phase II clinical development in Japan
Modality: Small molecule topical formulation
Mechanism / Target: Dermatologic action aimed at reducing malodor by addressing sweat gland activity and/or odor production pathways
Route / form: Topical application (cream/ointment for axilla)
Differentiation: Focused on a specific unmet dermatologic condition with a localized topical approach, representing a niche dermatology asset in mid‑stage development
Manufacturer #492
Leading clinical‑stage dermatology pharma with broad R&D, manufacturing and commercialization focus on skin diseases, expanding into metabolic and specialty areas. It pursues strategic collaborations and global development through regional subsidiaries and innovation partnerships. The organization emphasises quality, regulatory compliance and expanding patient‑centric solutions.